Panels

return to panel list

Global Health: Innovative Approaches for Improving Health in Developing Countries

This panel will discuss new technologies, drugs, delivery systems and models targeted at improving health among developing country populations e.g. by reducing maternal and infant mortality rates. Participants will discuss various innovative models that have been introduced, the successes and challenges they have experienced, and how these models are expected to evolve in the future.

Confirmed Panelists:

Moderator & Panelist Bios

Tom Kalil, Special Assistant to the Chancellor for Science and Technology, University of California Berkeley
Thomas Kalil is the Special Assistant to the Chancellor for Science and Technology at UC Berkeley. He develops major new multi-disciplinary research and education initiatives at the intersection of information technology, nanotechnology and biology. He develops a broad range of partnerships between the California Institutes of Science and potential stakeholders in industry, government, foundations, and non-profits.

Thomas also serves as the Chair of the Global Health Working Group of the Clinton Global Initiative that brings together a community of global leaders to devise and implement innovative solutions to some of the world's most pressing challenges.

Previously, Thomas served as the Deputy Assistant to President Clinton for Technology and Economic Policy, and the Deputy Director of the White House National Economic Council. He led a number of White House technology initiatives, such as the National Nanotechnology Initiative, the Next Generation Internet, bridging the digital divide and e-learning.

Martha Campbell, Ph.D., President, Venture Strategies for Health and Development
Dr. Campbell is the founder and President of Venture Strategies, a non-profit organization that works with medical leaders, government officials and pharmaceutical manufacturers around the world to find ways to make high quality, low cost, off-patent products available to low income people through market distribution systems.

Dr. Campbell is a political scientist and health policy specialist focusing on sustainability, scale and market mechanisms in developing country projects. Previously she directed the population program of the David and Lucille Packard Foundation. She is a Lecturer in the School of Public Health, University of California, Berkeley. Her degrees are from Wellesley College and the University of Colorado.

Dr. Nap Hosang, M.D., Obstetrician-gynecologist, Kaiser Permanente; Lecturer, School of Public Health, UC Berkeley
Dr. Hosang is a practicing Ob/Gyn and physician administrator at the Kaiser Permanente Medical Center in Hayward, California. He is also a lecturer at the School of Public Health, UC Berkeley, where he is part of the International Health teaching faculty. Dr. Hosang currently heads the Interdisciplinary MPH program that targets mid-career physicians and other professionals interested in public health.

Prior to Berkeley, Dr. Hosang spent 4 years on faculty at the University of the West Indies, in Kingston. His special interests are in health management systems targeted at reducing maternal and child mortality in developing countries. Dr. Hosang also started the Berkeley Center for Entrepreneurship in International Health and Development to facilitate entrepreneurial ventures that improve the availability of reproductive health commodities in developing countries.

Dr. Chundak Tenzing, Director of Sight Programs, Seva Foundation
Prior to joining Seva Dr. Tenzing was a medical director at the Himalayan Sight Programs based in Nepal. Prior to that Dr. Tenzing was a fellow at the Cornea Eye Institute in Hyderabad. Dr. Tenzing has a Masters in Public Health from Johns Hopkins University and is also an ophthalmologist.

Clifford Samuel, Senior Director, International Access Operations, Gilead
Clifford Samuel is Gilead's Senior Director of International Access Operations Mr. Samuel has been instrumental in the launch of five oral HIV and hepatitis B antiviral treatments: Viread, Emtriva, Truvada, Atripla, and Hepsera. He is also responsible for developing and exponentially expanding Gilead's National Account's team into three distinct divisions in order to keep pace with Gilead's growth within the antiviral marketplace. He was previously appointed as Gilead's Senior Director of Commercial Operations.

Prior to joining Gilead Sciences Mr. Samuel was a sales representative at ICI Pharmaceuticals focusing on the cardiovascular market. Following his tenure at ICI, he joined Glaxo Pharmaceutical' s HIV/Oncology Specialty Division, where he launched 3TC and represented AZT.

Mr. Samuel earned his degree in mechanical engineering from the New Jersey Institute of Technology. He serves on the Community Advisory Board for UCSF AIDS Health Project (AHP) and the New Jersey Institute to Technology Honors Program Board.